Lupin pharmaceuticals has entered into an agreement with Nichi-Iko for the distribution, promotion, and sale of its proposed biosimilar etanercept, YLB113, in Japan.
Lupin pharmaceuticals announced this week that it has entered into an agreement with Nichi-Iko for the distribution, promotion, and sale of its proposed biosimilar etanercept, YLB113, in Japan.
The proposed biosimilar, which is awaiting Japanese regulatory approval, was developed by YL Biologics in a joint venture between a subsidiary of Lupin, Lupin Atlantis Holdings SA, and Yoshindo. In March, YLB113 was submitted for regulatory approval to the Pharmaceuticals and Medicals Device Agency (PMDA) in Japan following conclusion of a phase 3 study.
The study was a 52-week, multinational, randomized, double-blind, controlled trial that included more than 500 patient with rheumatoid arthritis (RA) in 11 countries. The trial sought to determine the efficacy and safety of YLB113 compared directly with the reference etanercept product, Enbrel.
Researchers found that the safety and immunogenicity of YLB113 were similar to those of the reference product. In addition, the study achieved its primary endpoint of equivalent improvement in RA, as measured by the American College of Rheumatology’s criteria for 20% improvement, or ACR20.
“The successful commercialization of our first biosimilar will help our foray into the fast-growing biologics space and also provide patients in Japan access to a high quality, affordable alternative,” said Nilesh Gupta, managing director of Lupin Limited in a statement.
If it receives regulatory approval, the product will be launched in Japan by Nichi-Iko.
In addition to filing the potential biosimilar for approval in Japan, Lupin has also submitted a marketing authorization application for YLB113 to the European Medicine’s Agency for the treatment of RA, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.